Oryx GmbH & Co. KG is a clinical-stage biotech company near Munich developing innovative therapies against cancer from multi-stage selected academic cancer projects. The company has built a singular pipeline comprising three products: an oncolytic virus against various solid tumors, which is suitable as a monotherapy and as a combination partner (bevacizumab, CPI and cell-based therapies), and two therapeutic vaccines against high-risk human papilloma virus associated cancers and microsatellite unstable (MSI-H) cancers, respectively. All pipeline products have demonstrated proof of concept in clinical trials, and follow up-programs show promising further data. The pipeline products are well positioned and ready for further respectively final development and subsequent marketing by pharma.
Unlike many other biotech companies, Oryx GmbH & Co. KG combines in-house expertise with outsourced execution by world-renowned partners, such as the German Cancer Research Center or the National Center for Tumor Diseases. This allows to draw on independent experts and professional resources only as needed and guarantees a lean operating structure, enabling capital-efficient pipeline development and creating maximum value for patients and the company's investors.
Oryx GmbH & Co. KG is funded by private investors to achieve the maximum flexibility necessary to respond to the dynamic and evolving biotech scene. The company is, however, constantly evolving and open for different funding opportunities. Feel free to get in touch with us at any time.